8-K filed November 16, 2023, 6:59 PM ET ticker QTTB CIK 0001661998

M&A confidence high sentiment neutral materiality 0.80

Homology Medicines to merge with Q32 Bio, valuing Q32 at $195M; CEO and CFO terminated

Q32 Bio Inc.

All-stock merger ascribes Q32 equity value of $195M; Homology equity ~$80M; Q32 stockholders to receive Homology common shares.
Q32 to raise $42M in concurrent financing from accredited investors immediately before close.
Combined board to have 9 members: 2 from Homology, 7 from Q32 (indicating Q32 control).
Q32 holders with 74.1% of Q32 capital stock and Homology holders with 18.2% of common stock support deal via support agreements.
CEO Albert Seymour and CFO W. Bradford Smith terminated; Paul Alloway named President/COO/PEO; Charles Michaud named VP/Controller/Treasurer.

item 1.01 item 3.02 item 5.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

W. Bradford Smith

Chief Financial and Business Officer and Treasurer

QTTB · Q32 Bio Inc.

Effective: 2023-11-17
Filed: November 16, 2023, 6:59 PM ET

the Board terminated the employment of each of Albert Seymour, Ph.D. and W. Bradford Smith, effective as of November 17, 2023.

Departed

Albert Seymour

Director

QTTB · Q32 Bio Inc.

Effective: 2023-11-17
Filed: November 16, 2023, 6:59 PM ET

Dr. Seymour resigned from the Company’s board of directors, effective as of November 17, 2023.

Departed

Albert Seymour

President and Chief Executive Officer

QTTB · Q32 Bio Inc.

Effective: 2023-11-17
Filed: November 16, 2023, 6:59 PM ET

the Board terminated the employment of each of Albert Seymour, Ph.D. and W. Bradford Smith, effective as of November 17, 2023.

Appointed

Paul G. Alloway

President, Chief Operating Officer and Secretary

QTTB · Q32 Bio Inc.

Effective: 2023-11-17
Filed: November 16, 2023, 6:59 PM ET

the Board (i) appointed Paul G. Alloway, Ph.D., who currently serves as the Company’s Chief Legal Officer and Secretary, as the Company’s President, Chief Operating Officer and Secretary, and designated Dr. Alloway as the Company’s principal executive officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

W. Bradford Smith was terminated as Chief Financial and Business Officer and Treasurer at Q32 Bio Inc..

Action: terminated
Role: Chief Financial and Business Officer and Treasurer

Exact text from the filing

the Board terminated the employment of each of Albert Seymour, Ph.D. and W. Bradford Smith, effective as of November 17, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Albert Seymour resigned as Director at Q32 Bio Inc..

Action: resigned
Role: Director

Exact text from the filing

Dr. Seymour resigned from the Company’s board of directors, effective as of November 17, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Albert Seymour was terminated as President and Chief Executive Officer at Q32 Bio Inc..

Action: terminated
Role: President and Chief Executive Officer

Exact text from the filing

the Board terminated the employment of each of Albert Seymour, Ph.D. and W. Bradford Smith, effective as of November 17, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Paul G. Alloway was appointed as President, Chief Operating Officer and Secretary at Q32 Bio Inc..

Action: appointed
Role: President, Chief Operating Officer and Secretary

Exact text from the filing

the Board (i) appointed Paul G. Alloway, Ph.D., who currently serves as the Company’s Chief Legal Officer and Secretary, as the Company’s President, Chief Operating Officer and Secretary, and designated Dr. Alloway as the Company’s principal executive officer

View on SEC.gov

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-278334

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.